U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873801) titled 'A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis' on Oct. 08.
Brief Summary: The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: Lebrikizumab
Lebrikizumab SC injection.
OTHER: Placebo
Matching placebo SC injection.
DRUG: Lebrikizumab
L...